Engineering Longer-Lasting Somatostatin Peptide Analogs for Radioactive Cancer Treatment | Research

The takeaway

Two modified somatostatin antagonist peptides with albumin-binding domains showed improved blood circulation for radionuclide cancer therapy, but the trade-off between longer blood residence and reduced tumor targeting remains a challenge.

30–48-fold lower affinity
Adding albumin-binding domains to extend blood circulation came at the cost of substantially reduced somatostatin receptor binding affinity compared to the parent peptide.

What the researchers found

Two JR11 analogs (8a and 8b) carrying albumin-binding domains were synthesized and labeled with lutetium-177 for radionuclide therapy evaluation:

- Both achieved >97% radiochemical purity and >95% stability in PBS and mouse serum

- 8a showed better human albumin binding affinity than 8b

- Both analogs had significantly lower SSTR2 binding affinity than parent JR11 (30-fold and 48-fold lower, respectively)

- Both showed high cell uptake but low internalization rate (consistent with antagonist behavior)

- SPECT/CT imaging showed high tumor accumulation for [177Lu]Lu-8a at 4, 24, 48, and 72 hours post-injection, comparable to JR11

- [177Lu]Lu-8b showed no tumor uptake despite in vitro activity

- Ex vivo biodistribution revealed increasing tumor uptake over time for 8a, but its extended blood circulation resulted in an unfavorable biodistribution profile for therapeutic use

Why it matters

Peptide receptor radionuclide therapy (PRRT) is an established treatment for neuroendocrine tumors, but optimizing peptide pharmacokinetics remains critical. While longer blood circulation could increase radiation delivered to tumors, this study reveals the trade-off: extended circulation also increases radiation to healthy tissues. Finding the right balance is essential for making safer, more effective radioactive cancer treatments.

How the study worked

Researchers designed and synthesized two JR11 peptide analogs incorporating albumin-binding domains. Both were radiolabeled with lutetium-177 and characterized for radiochemical purity and stability. In vitro assays measured albumin binding, SSTR2 affinity, cell uptake, and internalization. In vivo SPECT/CT imaging tracked tumor accumulation over 72 hours in tumor-bearing mice. Ex vivo biodistribution studies quantified organ-level uptake to assess therapeutic suitability.

What this study cannot tell us

Both analogs showed substantially reduced SSTR2 binding affinity compared to the parent peptide JR11, which may limit therapeutic efficacy. One analog (8b) showed no tumor uptake in vivo despite in vitro activity, highlighting the gap between bench and in vivo performance. The study was preclinical (mouse models only). The unfavorable biodistribution of 8a means neither analog is suitable for clinical development in its current form.

How to read the evidence

This is a preclinical study involving peptide synthesis, in vitro characterization, and in vivo evaluation in mouse tumor models. While methodologically thorough, it represents early-stage radiopharmaceutical development with results that were not therapeutically favorable.

When this study was published

Published in 2022, this study contributes to ongoing research in somatostatin receptor-targeted radionuclide therapy. The challenges identified here remain relevant to current efforts to optimize peptide radiopharmaceuticals.

The bigger picture

This study illustrates a common challenge in radiopharmaceutical development: modifying peptides to improve one property (blood residence time) can compromise others (receptor affinity, biodistribution). SSTR2-targeting peptides are already clinically successful (e.g., Lutathera/[177Lu]Lu-DOTATATE), and research into antagonist-based approaches like JR11 aims to improve tumor-to-background ratios. This work provides valuable data on albumin-binding strategies, even though the current analogs weren't therapeutically optimal.

Questions still open

Can albumin-binding domain modifications be optimized to extend circulation without the 30-48-fold loss in receptor binding affinity?
Why did analog 8b show no tumor uptake in vivo despite demonstrating in vitro cell uptake?
Could alternative strategies for extending blood residence time (e.g., PEGylation, different linkers) avoid the biodistribution problems seen here?

Common questions

What is peptide receptor radionuclide therapy?

It's a cancer treatment where radioactive atoms are attached to peptides that specifically target receptors on tumor cells. The peptide acts like a guided missile, delivering radiation directly to the cancer while minimizing damage to healthy tissues. It's currently used to treat certain neuroendocrine tumors.

Why would making a drug last longer in the blood be a problem?

While longer blood circulation gives the drug more time to reach the tumor, it also means radioactive material stays in the bloodstream longer, exposing healthy organs like the kidneys and bone marrow to more radiation. Finding the right balance between staying long enough to target tumors and clearing fast enough to protect healthy tissue is a key challenge.

Read the original research

Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors.

Pharmaceuticals (Basel, Switzerland), 15(9)

View on PubMed ↗Publisher’s paper ↗

Citation

Koustoulidou, Sofia; Handula, Maryana; de Ridder, Corrina; Stuurman, Debra; Beekman, Savanne; de Jong, Marion; Nonnekens, Julie; Seimbille, Yann. (2022). Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors.. Pharmaceuticals (Basel, Switzerland), 15(9). https://doi.org/10.3390/ph15091155